We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Office of Management and Budget clarified President Trump’s new “one in, two out” regulations order, narrowing its scope to significant regulations with an economic impact of over $100 million per year, and new guidance documents considered on a case-by-case basis. Read More
Sponsors seeking approval for an interchangeable biosimilar should plan to conduct a switching study using a U.S.-licensed comparator product and primary endpoints that assess clinical pharmacokinetics (PK) and pharmacodynamics (PD). Read More
Two lawmakers behind the Cures Act have asked the Office of Management and Budget to clarify whether the federal hiring freeze applies to the FDA, raising concerns that the freeze could disrupt the implementation of the bipartisan law and the passage of user fee agreements. Read More
Two congressmen introduced right-to-try legislation in the House this week, which could find broad support from Congress and the White House. Read More
More than 160 biotech executives, investors and researchers have signed on to a letter opposing President Trump’s executive order restricting immigration from seven Middle Eastern and African countries. Read More
Teva Pharmaceuticals has been named in a patent infringement lawsuit as it attempts to develop a generic version of Belbuca, a long-acting opioid painkiller sponsored by BioDelivery Sciences International and Arius Two. Read More